Answers are grounded in this paper and cite their sources.
This study is aimed to investigate the nootropic potential of different doses (400, 500 and 600 mg/kg) of methanolic bark extract of Murraya koenigii (L.) Spreng. in healthy or amnesic mice induced by scopolamine and diazepam. The passive avoidance paradigm (PAP) and elevated plus maze (EPM) were used as behavioral models for memory assessment. Mice were subjected to scopolamine and diazepam induced amnesic models. Different concentrations of methanolic bark extracts of M. koenigii were administered orally for 15 days. Post behavioral analysis acetylcholine content was determined in brain extract. Preliminary qualitative phytochemical study of methanolic bark extract of M. koenigii expressed the existence of alkaloids, flavonoids, saponins, steroids, phenols, glycosides and tannins. There were significantly decrease in transfer latencies on EPM and increase in step down latencies on PAP. Additionally, 600 mg/kg dose significantly (p<0.001) attenuated the amnesic effect induced by scopolamine and diazepam. The 500 and 600 mg/kg concentrations of methanolic bark extract significantly (p<0.05) enhanced the role of acetylcholine in memory improvement. The carbazole alkaloids present in M. koenigii crude bark extract have significant nootropic effect as it increases acetylcholine content in brain at a dose of 500 and 600 mg/kg concentrations. Thus, the methanolic extract of M. koenigii bark may prove to be an effective nootropic agent in management of Alzheimer's disease having its underlying mechanisms that involves increasing cholinergic transmission.
No takes yet. Share an insight, caveat, or question.
Siddique et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: